During the corresponding time, Travere Therapeutics Inc recorded a revenue increase by 48.17 % year on year, sequentially revenue grew by 33.32 %. While revenue at the Travere Therapeutics Inc 's corporate clients
Travere Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including those reimbursed under Medicaid and other state programs. Its operations involve interactions with doctors and hospitals, some of which may be state-controlled. The company also engages with private third-party payers within healthcare benefit programs. Its markets include federal and state healthcare programs as well as entities involved in healthcare delivery and payment.
San Diego A New Hope in FSGS In an impressive stride for kidney disorder therapeutics, Travere Therapeutics, Inc. (Nasdaq: TVTX) has unveiled promising findings from its Phase 3 DUPLEX Study at the 2025 American Society of Nephrology (ASN) Kidney Week. This announcement marks a significant milestone for patients battling focal segmental glomerulosclerosis (FSGS), a rare kidney disease that leads to kidney failure in a majority of affected individuals.The study s data highlight the efficacy of Travere s leading investigational drug, FILSPARI (sparsentan), in managing FSGS. Notably, patients administered with FILSPARI were notably more likely to achieve proteinuria levels below 0.7 g/g as compared to those o...
Travere Therapeutics, Inc., focused on innovative therapies for rare kidney diseases, has made significant strides concerning its lead product, FILSPARI (sparsentan). Recent updates from the U.S. Food and Drug Administration (FDA) and European Commission underscore the product’s potential in treating both Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN). The implications of these developments are vast, impacting both clinical practice and patient outcomes. FDA’s Update on FILSPARI for FSGS In a noteworthy announcement, Travere Therapeutics disclosed that the FDA has decided that an advisory committee meeting for the supplemental New Drug Application (sNDA) regarding FILSP...
In a significant advancement for renal medicine, Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor have announced that the European Commission has granted full marketing authorization (MA) for FILSPARI (sparsentan) for the treatment of adult patients with primary IgA nephropathy. This decision marks the conversion of the initially granted conditional marketing approval (CMA) to a standard MA, thereby solidifying FILSPARI s position in the treatment landscape for this challenging disease.Filspari is now approved for patients who exhibit a urine protein excretion of 1.0 grams per day or a urine protein-to-creatinine ratio of 0.75 grams per gram. This therapeutic move is expected to significantly impact t...
In recent tumultuous market conditions, the biotechnology sector has found itself under increased scrutiny. Among these companies is Travere Therapeutics, Inc. (NASDAQ: TVTX), which has caught the attention of Bronstein, Gewirtz and Grossman, LLC. On October 7, 2024, the law firm announced an investigation into potential claims affecting investors who purchased Travere securities. This development presents an opportunity for those concerned about their investments to seek additional clarification and support.As a company dedicated to advancing therapies for rare diseases, Travere Therapeutics has a public image tied closely to its innovative drug pipeline. Despite its promising position in the market, the fi...
: Travere Therapeutics, Inc., a biopharmaceutical company focused on developing transformative therapies for serious conditions, has announced its participation in several upcoming investor conferences this August. This article aims to summarize the key details of the company s engagement strategy and its implications for stakeholders in the biopharmaceutical sector. In the realm of biopharmaceutical innovation, effective communication with stakeholders is paramount. Travere Therapeutics, Inc., headquartered in San Diego and traded on the NASDAQ under the symbol TVTX, exemplifies this through its proactive engagement with investors. As the company gears up to present at various investor conferences in Augu...
In recent years, sparsentan, marketed as FILSPARI, has emerged as a promising treatment for IgA nephropathy (IgAN). Travere Therapeutics, the biopharmaceutical company behind FILSPARI, recently presented groundbreaking data at the National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress, which highlighted the drug s potential as a foundational therapy. This article aims to interpret the presented information, outline the significant findings, and assess their impact on Travere Therapeutics.Interpretation of the Presented s: The articles discuss the presentations made by Travere Therapeutics, emphasizing the groundbreaking potential of FILSPARI as a foundational the...
Travere Therapeutics and CSL Vifor Advance Treatment for IgA Nephropathy with EC Approval of FILSPARI (sparsentan): A Major Milestone in Non-Immunosuppressive TherapyIn a significant breakthrough for patients living with IgA Nephropathy (IgAN), Travere Therapeutics and CSL Vifor have announced the European Commission s approval of FILSPARI (sparsentan) for the treatment of this rare kidney disease. This approval marks a historic moment as FILSPARI becomes the first-ever non-immunosuppressive treatment to be authorized for the management of IgAN in Europe. With IgAN affecting millions globally, this milestone offers renewed hope for patients who have been longing for more effective treatment options.Understan...
Travere Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including those reimbursed under Medicaid and other state programs. Its operations involve interactions with doctors and hospitals, some of which may be state-controlled. The company also engages with private third-party payers within healthcare benefit programs. Its markets include federal and state healthcare programs as well as entities involved in healthcare delivery and payment.
Sources:
Travere Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Travere Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Travere Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
168.56 %